亿帆医药：收到褪黑素颗粒药品注册上市许可申请受理通知书

Core Viewpoint - Yifan Pharmaceutical (002019) has received a production registration acceptance notice from the National Medical Products Administration for melatonin granules, aimed at improving sleep difficulties in children aged 6 to 15 with neurodevelopmental disorders [1] Company Summary - Yifan Pharmaceutical's wholly-owned subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., is the entity that received the registration notice [1] - The melatonin granules are specifically designed for children with neurodevelopmental disorders, indicating a targeted approach in the pediatric pharmaceutical market [1] Industry Summary - The approval of melatonin granules reflects ongoing developments in the pediatric healthcare sector, particularly in addressing sleep-related issues among children [1] - This move may enhance the competitive landscape for companies focusing on neurodevelopmental treatments and pediatric medications [1]